trending Market Intelligence /marketintelligence/en/news-insights/trending/m_ihusvjcdkdrp6csjktlq2 content esgSubNav
In This List

Allergy Therapeutics nonexecutive director retires; replacement named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allergy Therapeutics nonexecutive director retires; replacement named

Allergy Therapeutics PLC added Scott Leinenweber as a nonexecutive director, succeeding Jeff Barton, who retired from the board.

Barton joined the company's board in February 2017.

Leinenweber was nominated by Abbott Laboratories where he currently serves as vice president of investor relations and licensing & acquisitions. Abbott Laboratories owned 16.21% of the company as of Aug. 1, according to S&P Global Market Intelligence data.

U.K.-based Allergy Therapeutics is a biotechnology company focused on the treatment and diagnosis of allergic disorders.